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are 1.61 times less likely to relapse; those with sponsors are 1.64 times less likely to
relapse), cetertis paribus. Adjustor covariates include: Global Assessment of Func-
tioning, addiction severity, DSM diagnosis and length of stay. CONCLUSIONS:
Since this survival model relates the time that passes before relapse occurs to
known risk factors for relapse, this research will help treatment providers identify
not only the best types of interventions but also the correct timing of interventions.
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OBJECTIVES: In previous studies, psychopathology particularly negative, depres-
sive and cognitive syndromes adversely influenced health-related quality of life
(HRQoL). The objective of the study was to examine the relationship between
schizophrenia symptoms and the HRQoL dimensions of the EQ-5D descriptive
system. METHODS: This was a cross-sectional study conducted at the Psychiatric
Clinic, Universiti Kebangsaan Malaysia Medical Centre. Patients were assessed for
symptom severity using the Clinical Global Impressions-Schizophrenia (CGI-SCH)
severity scale (scores range from (1) no illness to (7) most severe possible) by the
attending clinicians. Patients’ perceived health states in 5 dimensions (mobility,
self-care, usual activities, pain/discomfort and anxiety/depression) with 3 levels of
response; (1) no problems, 2 (moderate problems) and 3 (extreme problems) were
evaluated using the EQ-5D descriptive system. The association between the 2
scales were examined by Spearman rank correlations. RESULTS: A total of 222
out-patients (Mean age 37.7, SD 10.1; Mean duration of illness  11.42, SD8.0)
with a DSM-IV chart diagnosis of schizophrenia participated in the study. There
was a moderate positive correlation between the EQ-5D ‘usual activities’ dimen-
sion and each of the CGI-SCH overall, depressive and cognitive symptom dimen-
sion scores (rs  0.35, 0.37 and 0.31, respectively & for all p  0.01). A significant
moderate correlation was also found between the EQ-5D ‘anxiety/depression’ and
the CGI-SCH depressive symptom dimension scores (rs  0.35, p  0.01). Weak
correlations were found between the CGI-SCH symptoms and other EQ-5D dimen-
sions scores (rs ranges from 0.16 to 0.26, p 0.01). CONCLUSIONS: In chronic
schizophrenics living in the community, worsening of overall, depressive and cog-
nitive symptoms were moderately associated with deterioration in patients’ usual
life activities and worsening of depressed mood was moderately associated with
worsening of anxiety or depression states. Schizophrenia syndromes were only
weakly associated with patients’ mobility, self-care and sense of pain or discom-
fort.
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OBJECTIVES: To ascertain changes in Health related Quality of Life (HRQL) among
young heroin users after one year follow-up.METHODS:Heroin users (18-30y) were
recruited in outdoor settings in three Spanish cities (Barcelona, Madrid, Seville)
from 2001 to 2003 and followed up, on average, 1.4(SD:0.6) years later. Standardised
laptop interviews included socio-demographic data, drug use patterns, health re-
lated issues, the Severity of Dependence Scale (SDS) and the Nottingham Health
Profile (NHP). For bivariate analyses, non parametric Mann-Whitney U and
Kruskal-Wallis tests were used. Factors associated to NHP score changes over time
were analysed through a multiple linear regression taking into account socio-de-
mographic factors, consumption patterns and health related variables.RESULTS:A
total of 628 subjects (72.5% males), mean age 27.9 (SD:3.4) years were followed
(63.4%). Mean total NHP score improved, from 36.4 (SD:24.2) at baseline to 27.0
(SD:22.4) at follow-up. Variables associated with total NHP score worsening were
HIV infection during follow-up, having experienced an overdose during the last 12
months and psychiatric treatment ever; conversely, total NHP score improved
among those who got a job by the end of the study. Each additional substance with
a weekly regular use and higher SDS scores for both cocaine and heroin, measured
as a difference from baseline values, were also related to worsening total NHP
score. We observed an interaction between severity of heroin dependence (as mea-
sured with SDS) and methadone maintenance treatment. The NHP total score only
improved, with decreasing heroin SDS, among drug users in methadone mainte-
nance treatment.CONCLUSIONS:HRQL improved over 12 months for young heroin
users. The main variables independently related with HRQL were changes in her-
oin and cocaine SDS. Further holistic models taking into account social variables
are needed.
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OBJECTIVES: Developing practical strategies to incorporate quality of life (QoL)
data in clinical management is an unmet need, and using quality of life (QoL) as a
predictor of clinical event is a new trend in outcomes research. The objective of this
study was to investigate relapse rate as a function of QoL in schizophrenic patients.
METHODS: We used data from EuroSC, a multicenter 2-year cohort study con-
ducted in France, England and Germany. We first examined the association be-
tween occurrence of relapse and baseline QoL, as measured by SF36 mental com-
posite score (MCS) and physical composite score (PCS), by EQ-5D and QOLI
subjective score. Then bivariate analyses were performed to identify confounding
factors (CF). Finally CF and QoL were incorporated in several multivariate Cox
models. RESULTS: Our sample consisted in 922 patients with schizophrenia. QoL
was found to be lower for those who relapsed (418 patients with MCS 40.1, PCS
47.1, EQ-5D utility  0.70 and QOLI  4.65 vs. 504 patients with MCS  43.9
(p0.0001), PCS  49.2 (p0.001), EQ-5D utility  0.77 (p0.0001), and QOLI  4.8
(p0.01)). Bivariate analyses identified several outcomes: age, gender, severity of
disease, depression, antipsychotic medication, compliance, subjective side effects
and functioning. Multivariate Cox models confirmed that a higher level of QoL
predicts a significantly lower rate of relapse at 2 years (HR  0.94, p0.03 for MCS;
HR 0.89; p0.01 for PCS; HR0.97; p0.001 for EQ-5D utility; HR0.83; p0.004 for
QOLI). CONCLUSIONS: This study shows that QoL can be considered as a mediator
of relapse in schizophrenia, independently of clinical severity scales. These results
are consistent with new research trends. Our findings can contribute to develop
credible strategies on how to integrate QoL data in clinical practice.
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OBJECTIVES: To understand the association of antidepressant-related sexual dys-
function with degree of enjoyment and satisfaction from daily activities, and cur-
rent medication. METHODS: Employed individuals (18 years of age) with depres-
sion (excluding bipolar disorder) completed a web-based computer-generated 25-
minute survey (population identified by Harris Interactive). Sexual dysfunction
(SD) was assessed using the Arizona Sexual Experience (ASEX) Scale on 5 compo-
nents of sexual functioning (Drive, Arousal, Penile Erection/Vaginal Lubrication,
Orgasm, Satisfaction); each rated on a 6-level ordinal scale (higher scores indicate
increased SD). Using distribution among current antidepressant users, overall SD
score was categorized into quartiles (lowest quartile represented better sexual
functioning). Degree of enjoyment and satisfaction related to general activity and
current medication was measured using a 5-point ordinal scale (1very poor and
5very good) using the Quality of Life Enjoyment and Satisfaction Questionnaire –
Short Form (QLESQ-SF). A summary “percent-of-max” score for general activity
items, transformed to 5-level ordinal variable employing cut-points of 20, 40, 60
and 80%, was used (20% represented the poorest experience). Gender stratified
cumulative logit models were used to estimate effect of SD on QLESQ measures.
RESULTS: Of 1,521 respondents, 872 (57%) reported current antidepressant use
(60.6% female, mean age 49.9 13.5 years). Among antidepressant users, compared
to the first SD quartile, odds of being in a poorer overall “percent-of-max” score (i.e.,
lower enjoyment/satisfaction) were greater in the highest (4th) SD quartile for both
males (odds ratio [OR] 3.03; p0.0007) and females (OR1.96; p0.0021). Sexual
dysfunction was associated with lack of satisfaction with medication for both gen-
ders: (males - 3rd SD quartile (OR2.17; p0.001); highest SD quartile (OR3.33;
p0.0003); females - highest SD quartile (OR1.49; p0.06)). CONCLUSIONS: These
data suggest that antidepressant-related SD may be associated with diminished
enjoyment and satisfaction with daily activities and current medication. Such per-
ceptions may impact eventual treatment outcomes.
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OBJECTIVES: There has been increased attention to the antipsychotic treatment of
negative symptoms in schizophrenia and the potential impact that this could have
on various functional outcomes. We compared the relative effects of negative
symptoms on functioning as compared to other symptoms. METHODS: Data are
from 18 months of the National Institute of Mental Health (NIMH) CATIE trial of
chronic schizophrenia (n1447). Measures were the Positive and Negative Syn-
drome Scale (PANSS), functioning from the Heinrich’s (Instrumental role, Common
place objects and activities) and items from the Lehman Quality of Life Scales
(Leisure activities, Instrumental activities of daily living). Quality of life items mea-
suring negative symptoms were excluded. Correlations between the five PANSS
factors and the functional measures were examined at baseline and change. Func-
tioning items were summed to create a standardized total score. Multiple regres-
sion was used to predict the functioning total score at baseline using the five PANSS
factors and change in functioning using change on the PANSS factors. RESULTS:
The negative symptom factor correlated more strongly than other symptom fac-
tors with functioning at baseline and change scores. Multiple regression predicting
functioning at baseline including all five PANSS factors showed that the negative
symptom factor was the strongest predictor, almost three times that of positive
symptoms (r-0.25 vs. r-0.07). A similar multiple regression predicting change in
total functioning with change on PANSS also found that the negative factor was the
best predictor and was double that of the positive factor (r-0.08 vs. r-0.045).
CONCLUSIONS: Baseline and change in functioning were more strongly related to
the PANSS negative factor than the other four PANSS factors. Since we focused on
negative symptoms we chose domains of functioning that did not overlap with
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